Mexico moves to increase regulatory efficiency, but prioritises generics
This article was originally published in SRA
Mexican authorities have introduced several new measures aimed at getting more drugs to the market more quickly. However, generic medicines manufacturers are most likely to benefit, because, as Mikel Arriola, commissioner of the health protection agency, COFEPRIS, recently told local companies, such products are the government's top priority1.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.